Selected research
Industry Growth & Trends
Global Anti-Neprilysin Antibody Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Anti-Neprilysin Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Anti-Neprilysin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Anti-Neprilysin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-Neprilysin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Anti-Neprilysin Antibody market include Bioprojet SCR, Cipla Limited, Novartis International AG, Oceanic Pharmachem Pvt. Ltd, Pharmaleads SA and Theravance Biopharma Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Anti-Neprilysin Antibody market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Anti-Neprilysin Antibody market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-Neprilysin Antibody market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-Neprilysin Antibody.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Anti-Neprilysin Antibody market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Anti-Neprilysin Antibody Market by Company
Bioprojet SCR
Cipla Limited
Novartis International AG
Oceanic Pharmachem Pvt. Ltd
Pharmaleads SA
Theravance Biopharma Inc.
Anti-Neprilysin Antibody Segment by Type
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Anti-Neprilysin Antibody Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Anti-Neprilysin Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Neprilysin Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Neprilysin Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Neprilysin Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Anti-Neprilysin Antibody companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Sacubitril
- TD-0714
- STR-324
- PL-265
- LHW-090
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Bioprojet SCR
- Cipla Limited
- Novartis International AG
- Oceanic Pharmachem Pvt. Ltd
- Pharmaleads SA
- Theravance Biopharma Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Anti-Neprilysin Antibody Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Anti-Neprilysin Antibody Market Size by Region (2021-2032)
- 1.4.1 Global Anti-Neprilysin Antibody Market Size by Region (2021-2026)
- 1.4.2 Global Anti-Neprilysin Antibody Market Size by Region (2027-2032)
- 1.5 Key Regions Anti-Neprilysin Antibody Market Size (2021-2032)
- 1.5.1 North America Anti-Neprilysin Antibody Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Anti-Neprilysin Antibody Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Anti-Neprilysin Antibody Market Size Growth Rate (2021-2032)
- 1.5.4 South America Anti-Neprilysin Antibody Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Anti-Neprilysin Antibody Market Size Growth Rate (2021-2032)
2 Anti-Neprilysin Antibody Market by Type
- 2.1 Type Introduction
- 2.1.1 Sacubitril
- 2.1.2 TD-0714
- 2.1.3 STR-324
- 2.1.4 PL-265
- 2.1.5 LHW-090
- 2.2 Global Anti-Neprilysin Antibody Market Size by Type
- 2.2.1 Global Anti-Neprilysin Antibody Market Size Overview by Type (2021-2032)
- 2.2.2 Global Anti-Neprilysin Antibody Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Anti-Neprilysin Antibody Market Size Forecasted by Type (2027-2032)
- 2.3 Global Anti-Neprilysin Antibody Market Size by Regions
- 2.3.1 North America Anti-Neprilysin Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Anti-Neprilysin Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Anti-Neprilysin Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Anti-Neprilysin Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Anti-Neprilysin Antibody Market Size Breakdown by Type (2021-2026)
3 Anti-Neprilysin Antibody Market by Application
- 3.1 Type Introduction
- 3.1.1 Retail Pharmacies
- 3.1.2 Online Pharmacies
- 3.1.3 Hospital Pharmacies
- 3.2 Global Anti-Neprilysin Antibody Market Size by Application
- 3.2.1 Global Anti-Neprilysin Antibody Market Size Overview by Application (2021-2032)
- 3.2.2 Global Anti-Neprilysin Antibody Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Anti-Neprilysin Antibody Market Size Forecasted by Application (2027-2032)
- 3.3 Global Anti-Neprilysin Antibody Market Size by Regions
- 3.3.1 North America Anti-Neprilysin Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Anti-Neprilysin Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Anti-Neprilysin Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Anti-Neprilysin Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Anti-Neprilysin Antibody Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Anti-Neprilysin Antibody Industry Trends
- 4.2 Anti-Neprilysin Antibody Industry Drivers
- 4.3 Anti-Neprilysin Antibody Industry Opportunities and Challenges
- 4.4 Anti-Neprilysin Antibody Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Anti-Neprilysin Antibody Revenue (2021-2026)
- 5.2 Global Anti-Neprilysin Antibody Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Anti-Neprilysin Antibody Key Company Headquarters & Area Served
- 5.4 Global Anti-Neprilysin Antibody Company, Product Type & Application
- 5.5 Global Anti-Neprilysin Antibody Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Anti-Neprilysin Antibody Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Anti-Neprilysin Antibody Players Market Share by Revenue in 2025
- 5.6.3 2025 Anti-Neprilysin Antibody Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Bioprojet SCR
- 6.1.1 Bioprojet SCR Company Information
- 6.1.2 Bioprojet SCR Business Overview
- 6.1.3 Bioprojet SCR Anti-Neprilysin Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Bioprojet SCR Anti-Neprilysin Antibody Product Portfolio
- 6.1.5 Bioprojet SCR Recent Developments
- 6.2 Cipla Limited
- 6.2.1 Cipla Limited Company Information
- 6.2.2 Cipla Limited Business Overview
- 6.2.3 Cipla Limited Anti-Neprilysin Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Cipla Limited Anti-Neprilysin Antibody Product Portfolio
- 6.2.5 Cipla Limited Recent Developments
- 6.3 Novartis International AG
- 6.3.1 Novartis International AG Company Information
- 6.3.2 Novartis International AG Business Overview
- 6.3.3 Novartis International AG Anti-Neprilysin Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Novartis International AG Anti-Neprilysin Antibody Product Portfolio
- 6.3.5 Novartis International AG Recent Developments
- 6.4 Oceanic Pharmachem Pvt. Ltd
- 6.4.1 Oceanic Pharmachem Pvt. Ltd Company Information
- 6.4.2 Oceanic Pharmachem Pvt. Ltd Business Overview
- 6.4.3 Oceanic Pharmachem Pvt. Ltd Anti-Neprilysin Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Oceanic Pharmachem Pvt. Ltd Anti-Neprilysin Antibody Product Portfolio
- 6.4.5 Oceanic Pharmachem Pvt. Ltd Recent Developments
- 6.5 Pharmaleads SA
- 6.5.1 Pharmaleads SA Company Information
- 6.5.2 Pharmaleads SA Business Overview
- 6.5.3 Pharmaleads SA Anti-Neprilysin Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Pharmaleads SA Anti-Neprilysin Antibody Product Portfolio
- 6.5.5 Pharmaleads SA Recent Developments
- 6.6 Theravance Biopharma Inc.
- 6.6.1 Theravance Biopharma Inc. Company Information
- 6.6.2 Theravance Biopharma Inc. Business Overview
- 6.6.3 Theravance Biopharma Inc. Anti-Neprilysin Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Theravance Biopharma Inc. Anti-Neprilysin Antibody Product Portfolio
- 6.6.5 Theravance Biopharma Inc. Recent Developments
7 North America
- 7.1 North America Anti-Neprilysin Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Anti-Neprilysin Antibody Market Size by Country (2021-2026)
- 7.3 North America Anti-Neprilysin Antibody Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Anti-Neprilysin Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Anti-Neprilysin Antibody Market Size by Country (2021-2026)
- 8.3 Europe Anti-Neprilysin Antibody Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-Neprilysin Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Anti-Neprilysin Antibody Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Anti-Neprilysin Antibody Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Anti-Neprilysin Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Anti-Neprilysin Antibody Market Size by Country (2021-2026)
- 10.3 South America Anti-Neprilysin Antibody Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-Neprilysin Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Anti-Neprilysin Antibody Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Anti-Neprilysin Antibody Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst